Validation of <scp>SIE</scp>/<scp>SIES</scp>/<scp>GITMO</scp> consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax-Reference-Cited by-同舟云学术

Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax

Published:2023-08-02 Issue:4 Volume:203 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Apolito Vincenzo¹²,Arrigo Giulia³,Vasseur Loic⁴,Olivi Matteo¹,Perrone Silvia³,Giai Valentina³,Secreto Carolina³,Di Biase Federica¹,De Simone Maria Carla⁵,Copia Carolina⁵,Gravetti Angela⁵,Freilone Roberto³,Bruno Benedetto¹,Lanzarone Giuseppe¹,Beggiato Eloise¹,Frairia Chiara³^ORCID,Audisio Ernesta³,D'Ardia Stefano³,Ferrero Dario¹^ORCID,Cerrano Marco³^ORCID,Ferrara Felicetto⁵

Affiliation:

1. Division of Haematology University of Turin Turin Italy

2. Pediatric Oncohematology, Stem Cell Transplantation and Cell Therapy Division Regina Margherita Children's Hospital Turin Italy

3. Division of Haematology, Department of Oncology Presidio Molinette, AOU Città della Salute e della Scienza di Torino Turin Italy

4. Hôpital Saint‐Louis, Assistance, Publique‐Hôpitaux de Paris Paris France

5. Division of Haematology AORN Cardarelli Naples Italy

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19022

Reference15 articles.

1. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

2. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia

3. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients

4. Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first‐line therapy with hypomethylating agents alone or in combination with Venetoclax

5. Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience